US FDA approves KEYTRUDA from Merck for adults with relapsed or refractory cHL
KEYTRUDA is the first anti-PD-1 therapy approved for adult patients with relapsed or refractory cHL after frontline therapy
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.